Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS IN DEXTROSE 5 versus PANWARFIN.
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of factor Xa and thrombin (factor IIa), thereby inhibiting coagulation.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
Initial IV bolus of 5000 units, followed by continuous IV infusion at 1300 units/hour (typically 25,000 units in 500 mL D5W at 26 mL/hour) for therapeutic anticoagulation; dose titrated to aPTT 1.5-2.5 times control.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (range 1–2 hours) after intravenous administration; dose-dependent: at therapeutic doses, half-life is about 1 hour; at higher doses, up to 2.5 hours. Clinical context: shorter half-life in pulmonary embolism, longer in renal impairment.
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal: negligible; primarily metabolized by the liver and reticuloendothelial system; small amount excreted unchanged in urine (<5%). Biliary/fecal: minimal.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category A/B
Category C
Anticoagulant
Anticoagulant